Research & Development News

RESEARCH & DEVELOPMENT NEWS

Nov. 20, 2009		Merck Receives CHMP Positive Opinion for New Fertility Treatment, ELONVA®
Nov. 17, 2009		Merck's Investigational Anacetrapib Phase IIb Study Results Presented at American Heart Association Annual Scientific Sessions
Nov. 13, 2009		Merck Announces Completion of Patient Enrollment in Phase III TRA-2°P-TIMI 50 Trial of SCH 530348, a Novel, Oral Antiplatelet PAR-1 Inhibitor
Sep. 24, 2009		Merck Statement on HIV Vaccine Trial
Sep. 14, 2009		New, Long-Term Data for Odanacatib, Merck's Investigational Cat K Inhibitor, Showed Positive Results in Treating Osteoporosis
Sep. 10, 2009		Merck Updates Status of Clinical Development Programs for Investigational CGRP Receptor Antagonist Treatments for Acute Migraine; MK-3207 Clinical Development Discontinued
Jul. 09, 2009		Merck & Co., Inc. and Portola Enter Worldwide License Agreement to Develop and Commercialize Betrixaban, a Novel Investigational Oral Anticoagulant for Cardiovascular Disease
Jun. 22, 2009		Merck & Co., Inc. and Drugs for Neglected Diseases initiative Collaborate to Find Treatments for World's Most Neglected Tropical Diseases
Jun. 05, 2009		Rolofylline Did Not Demonstrate Efficacy for Acute Heart Failure in Clinical Trial
Jun. 01, 2009		AstraZeneca and Merck & Co., Inc. Form Pioneering Collaboration to Investigate Novel Combination Anticancer Regimen
May 08, 2009		Studies of GARDASIL®, Merck's Cervical Cancer Vaccine, and HPV 16 Vaccine Component of GARDASIL Presented at International Papillomavirus Conference

Print
Share
Text Size

Product Pipeline

We have a robust pipeline, with a wide range of product candidates across each of phase of development.

Learn more

Related Information

SEC Filings

Privacy
Terms of Use
Site Map

Dec. 12, 2008		Merck Announces FDA Acceptance of Supplemental New Drug Application for ISENTRESS® (raltegravir) in Adult Patients Previously Untreated for HIV-1>
Oct. 13, 2008		GARDASIL®, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
Oct. 12, 2008		Results of Landmark Study of HIV Vaccine Published in The Lancet
Oct. 21, 2008		Dynavax and Merck & Co., Inc. Provide Update on U.S. FDA Clinical Hold on Investigational Vaccine HEPLISAV™
Oct. 07, 2008		Researchers to Evaluate a Once-Daily Investigational Dose of Raltegravir, Merck's Integrase Inhibitor, in an Investigational Population, Patients Previously Untreated for HIV-1
Oct. 02, 2008		Merck Discontinues Development of Investigational Medicine Taranabant for Obesity
Sep. 29, 2008		European Commission Adopts European Medicines Agency (EMEA) Recommendations on ARCOXIA™ (etoricoxib) 90 mg
Sep. 25, 2008		Merck & Co., Inc. and Japan Tobacco Inc. Sign Licensing Agreement for Novel Osteoanabolic Drug Candidate to Treat Osteoporosis
Sep. 16, 2008		Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Increased Bone Mineral Density (BMD) Over Two Years at Key Fracture Sites in Phase IIB Study
Sep. 06, 2008		Merck & Co., Inc.'s Investigational Migraine Treatment Telcagepant Relieved Migraine Pain and Symptoms in Latest Phase III Study
Aug. 05, 2008		Dynavax and Merck & Co., Inc. Announce Phase 3 Trial with Investigational Hepatitis B Vaccine (HEPLISAV™) Met its Primary Endpoint
May 27, 2008		Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone Metastases
May 21, 2008		ACHIEVE Imaging Study Discontinued
Apr. 28, 2008		Merck Receives Not Approvable Letter from FDA for MK-0524A (ER niacin/laropiprant)
Apr. 25, 2008		Schering-Plough/Merck Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
Apr. 24, 2008		Two Merck Medicines Recommended for Approval in the European Union
Apr. 17, 2008		Dynavax and Merck & Co., Inc. Update Status of Clinical Hold of Investigational Vaccine HEPLISAV™
Apr. 04, 2008		Merck's Investigational Rolofylline Associated with Improved Dyspnea and Preserved Renal Function in Acute Heart Failure Patients in a Phase III Pilot Study
Mar. 31, 2008		Patients Treated with Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE™) Reported Significantly Less Flushing Than Patients Treated with Niaspan™ in Phase III Study
Mar. 31, 2008		Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss
Mar. 31, 2008		Update on ACHIEVE: A Study of Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE™)
Mar. 17, 2008		Merck Scientists Apply Innovative Research Method to Identify Changes in Gene Networks Linked to Obesity
Mar. 17, 2008		Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational Vaccine HEPLISAV

Nov. 13, 2007		STEP Study Volunteers to be Informed Whether They Received Vaccine or Placebo
Nov. 07, 2007		Data from STEP Study Presented at Open Scientific Session Confirm Merck's Investigational HIV Vaccine was not Effective
Nov. 06, 2007		GTx, Inc. and Merck & Co., Inc. Enter Global Strategic Collaboration for the Development of SARMs, a Novel Investigational Class of Drugs to Treat Muscle Loss and other Musculoskeletal Conditions
Nov. 05, 2007		Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE™) Coadministered with Simvastatin Had Significant Additive Effects on LDL-C, HDL-C and Triglycerides in Phase III Study
Nov. 01, 2007		Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV™, an Investigational Hepatitis B Vaccine Currently in Phase 3
Oct. 23, 2007		Update regarding clinical trials of Merck's HIV vaccine candidate
Oct. 22, 2007		Statement by Merck & Co., Inc. Regarding FDA Nonprescription Advisory Committee Review of MEVACOR® (lovastatin)
Oct. 04, 2007		Merck's Investigational CETP-Inhibitor, MK-0859 (anacetrapib), Produced Positive Effects on Lipids with No Observed Blood Pressure Changes in Phase IIb Study
Sep. 21, 2007		Vaccination and Enrollment Are Discontinued in Phase II Trials of Merck's Investigational HIV Vaccine Candidate
Sep. 18, 2007		ISENTRESS™ (raltegravir), in Combination with Optimized Background Therapy (OBT), Provided Sustained Viral Suppression in Highly Treatment-Experienced Patients Infected with HIV, through 48 Weeks
Sep. 18, 2007		Increased Bone Mineral Density Seen in Phase IIB Study with Odanacatib, Formerly MK-0822, An Investigational Cathepsin K Inhibitor
Sep. 05, 2007		FDA Advisory Committee Unanimously Recommends Accelerated Approval of ISENTRESS™ (raltegravir), Merck's Investigational Oral Integrase Inhibitor, for Treatment of HIV
Sep. 02, 2007
Aug. 29, 2007		Merck Announces FDA Acceptance of NDA for CORDAPTIVE™ (ER niacin/laropiprant), Formerly Known as MK-0524A, an Investigational Lipid-Modifier
Aug. 28, 2007		Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet

RESEARCH & DEVELOPMENT NEWS

2008 Research & Development News

2007 Research & Development News

Product Pipeline

Related Information

Patients & Caregivers

Healthcare Professionals

Media & Investors

Job Seekers

Company Statements

Podcasts

RSS